TNKS and prostate carcinoma: Several approaches have been taken into account for inhibiting the Wnt pathway, such as LGK974, a drug that targets the Wnt-specific acyltransferase porcupine, and the tankyrase inhibitor XAV939 [46], and the growing interest in the inhibition of the Wnt pathway in prostate cancer models confirms the validity of the therapeutic hypothesis.